Anthropic Grew 14x and Booked an $80.7 Billion Loss: What the S-1 Arithmetic Says

Anthropic filed its S-1 with the US Securities and Exchange Commission on Monday, starting the countdown to what is expected to be one of the largest listings on record, with bankers reportedly aiming to price before Thanksgiving. The headline numbers are brutal and flattering at the same time: revenue of $16.29 billion for the six months to 30 June, against $1.16 billion a year earlier, and a net loss of $80.7 billion (Yahoo Finance, Reuters).

People close to the process are said to be valuing the company at about $1.5 trillion, down from roughly $2 trillion a week earlier after early financial details circulated among investors. Both numbers are astonishing. Neither tells you whether the business works. That requires arithmetic on the filing itself, which is what follows.

What the $80.7 billion loss actually is

It is mostly not money leaving the building. Of the $80.7 billion net loss, $72.4 billion is an accounting charge reflecting the rising fair value of bonds convertible into Anthropic shares, not cash spent on operations. That is 89.7% of the reported loss by our calculation, leaving $8.3 billion of loss that is not that one line item.

The operating line is the one to read. Operating loss narrowed to $693 million from $2.1 billion a year earlier, and adjusted operating income swung positive to $1.62 billion from a loss of $1.85 billion, which the company described as about a 10% margin. Our subtraction puts the gap between those two figures at $2.31 billion, or 14.2% of revenue: that is the stock-based compensation and non-cash charitable contribution that separates an operating loss of 4.25% of revenue from an adjusted profit of 9.94%. Every “$1.6 billion of profit” headline about this filing is really a statement about that 14.2%.

Three quarters, two growth rates

Quarterly revenue was $4.73 billion in the first quarter, $11.6 billion in the second and $16.8 billion in the third, the last figure disclosed at an investor meeting this month and reported by Reuters. The arithmetic on those three numbers is the whole investment case:

• First quarter to second quarter: +145.2%.
• Second quarter to third quarter: +44.8%.
• The step-down between those two growth rates is a factor of 3.2.

Two smaller cross-checks are worth doing. The filing says revenue grew 1,368% in the three months to 30 June; dividing $11.6 billion by 14.68 implies second-quarter 2025 revenue of roughly $0.79 billion, consistent with the annual base of $4.59 billion reported for 2025. And the first quarter plus the second quarter comes to $16.33 billion against the $16.29 billion reported for the half, a $40 million gap that is pure rounding. Anyone reconciling this filing to the dollar will lose that argument.

The multiple doubles depending on which quarter you annualise

Annualising the third quarter gives $67.2 billion of revenue. Annualising the first half doubled gives $32.6 billion. Same company, same filing, two very different denominators.

• At a $1.5 trillion valuation on third-quarter run rate: 22.3 times.
• At $2 trillion on the same run rate: 29.8 times.
• At $1.5 trillion on the first half doubled: 46 times.

Forward scenarios matter even more than the trailing choice. If the next sequential step decelerates by the same factor of 3.2, fourth-quarter growth lands near 14%: revenue of about $19.1 billion, a $76.4 billion run rate and 19.6 times at $1.5 trillion. If growth holds at 45%, the fourth quarter is $24.4 billion, the run rate $97.4 billion and the multiple falls to 15.4 times. On an adjusted margin near 10%, a 22.3-times multiple is an adjusted earnings yield of roughly 0.45%. That is the number a long-only investor is actually being offered.

What that looks like in yen

Reference rates published by the European Central Bank put the euro at $1.1188 and at 176.15 yen, which cross to about 157.45 yen per dollar. At that rate a $1.5 trillion valuation is about ¥236 trillion, and $2 trillion is about ¥315 trillion. The company’s first-half revenue converts to roughly ¥2.56 trillion, and the third-quarter figure to ¥2.65 trillion. Japanese investors will most likely reach the listing through funds and proxies rather than the stock directly, and they carry currency risk on top of valuation risk: a 10% move in dollar-yen is larger than the annual adjusted operating profit the filing discloses.

The risk section is where the deceleration is priced

Reuters reports that the filing discloses a month-long training pause and security breaches, alongside risk language warning that advanced systems could produce outputs that “could be interpreted as coercive, deceptive, or manipulative”, including behaviour resembling blackmail. The company’s own chief executive has publicly called for a slowdown in development. Read together with a sequential growth rate that fell by two thirds in a single quarter, the filing describes a company that is no longer in the phase where revenue doubles every ninety days. That is not a scandal. It is the normal shape of a maturing product line, arriving at a moment when the valuation assumes it has not arrived.

When this verdict flips

Our reading is conditional, and the conditions are arithmetic rather than narrative. At 22 times third-quarter run rate with a 10% adjusted margin, the buyer is underwriting at least 20% sequential growth into 2027 plus continued progress on compute cost; if fourth-quarter revenue comes in at or above $20.6 billion, the run rate is $82.3 billion and the multiple at $1.5 trillion drops to 18.2 times, at which point the price stops being an outlier. This analysis does not apply to three groups: anyone who needs cash returns from the position before 2029; anyone who treats the $72.4 billion convertible-note charge as fictional, because conversion adds shares and $1.5 trillion is a pre-dilution figure; and anyone buying because the adjusted line is positive, when that positivity depends on excluding 14.2% of revenue in stock.

What to watch

• Whether the roadshow prices at $1.5 trillion or the number moves again before listing.
• Fourth-quarter revenue and the sequential growth rate, the single cleanest test of the deceleration.
• The duration and cost of the disclosed training pause, and whether it recurs.
• Any gross-margin disclosure that separates inference cost from training cost.
• Yen pricing and hedging terms on any Japanese retail wrapper that tracks the listing.

Sources: Reuters, Anthropic’s soaring sales, steep losses put AI frenzy to IPO test; Reuters via US News, quarterly revenue detail; Fortune, the S-1 in numbers; Yahoo Finance, revenue and loss detail; ECB euro reference rates. Derived figures in this article were calculated by huanghuajian.com from the reported inputs above.